Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Basic and diluted income/(loss) per share (Tables)

v3.22.2.2
Basic and diluted income/(loss) per share (Tables)
 6 Months Ended
Jun. 30, 2022
Basic And Diluted Incomeloss Per Share  
Summary of basic and diluted earnings per share

    June 30,     June 30,  
    Six months ended  
    June 30,     June 30,  
    2022     2021  
    £     £  
Income/(loss) for the period     512,658       (2,648,192 )
Basic weighted average number of shares outstanding (1)     551,923       390,202  
Basic and diluted weighted average number of shares outstanding (1)     674,398       390,202  
                 
Basic income/(loss) per share     0.93       (6.79 )
Diluted income/(loss) per share     0.76       (6.79 )

 

  (1) On November 18, 2022, the Company undertook a reverse share split such that fifty issued ordinary shares were exchanged for one new share. The outstanding shares presented above reflect the fifty for one reverse share split.
Schedule of anti-dilutive weighted average shares

The following potential shares, presented to reflect the fifty for one reverse share split noted above are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted income/(loss) per share:

 

    2022     2021  
   

Six months ended

June 30,

    

Six months ended

June 30,

  
    2022     2021  
    Number of shares     Number of shares  
Convertible loan notes – assuming all loan notes are converted to equity (including all warrants are fully exercised)     33,768       -  
TC BioPharm Limited Enterprise Management Incentive Plan 2014     -       106,585  
2021 Share Option Scheme     52,305       -  
Warrants issued at the time of the IPO     318,443       -  
Options to subscribe for ordinary shares at a future date based on certain clinical and commercial milestones     -       15,891  
Dilutive effect securities     404,516       122,476